Cannabis Licence Greece: 2026 Business Guide

Searching for a cannabis licence Greece answer in 2026 can be confusing because people often use one phrase for three very different things: adult-use retail, medical cannabis production, and low-THC hemp or CBD commerce. The blunt but important starting point is this: Greece does not currently offer a normal recreational cannabis shop licence. The legal business route is the medical cannabis framework, where companies apply for tightly controlled authorisations to cultivate, process, manufacture, distribute, or export finished medicinal cannabis products.

That distinction matters for entrepreneurs, investors, pharmacists, wellness retailers, and consumers. A North American-style dispensary model cannot simply be copied into Athens, Thessaloniki, or the islands. Greek law treats THC cannabis as a controlled pharmaceutical category, while general consumer hemp products sit under separate low-THC rules and additional product restrictions. This guide explains the practical route, the authorities involved, the approval stages, and the traps that can turn a promising plan into a compliance problem.

The phrase “retail licence” is the first place many plans go wrong. Greece has a medical cannabis system, not an adult-use retail market. Medical cannabis was legalised in stages, and the key production framework is Law 4523/2018, available in English through the Greek Ministry of Rural Development and Food. That law created a route for final medicinal cannabis products made from Cannabis sativa L. with THC above the low-THC threshold, but it did not create recreational dispensaries.

In practice, the licence path is closer to pharmaceutical manufacturing than retail entrepreneurship. Applicants are dealing with controlled substances, industrial installation rules, agricultural inputs, pharmaceutical quality systems, security checks, and product approvals. The helpful way to think about it is simple: Greece may allow a qualified company to build a compliant medical cannabis production operation, but it does not allow a general adult-use storefront selling THC cannabis to walk-in customers.

Existing Puff ‘n Pass readers may also want to compare this with our broader medical cannabis Greece guide on EOF fees and exports and our consumer-focused Greece cannabis penalties explainer. The business opportunity is real, but it is narrow, technical, and not the same as opening a lifestyle shop.

✓ Key Compliance Takeaway

• ✓ No ordinary recreational dispensary licence exists in Greece in 2026.
• ✓ The realistic route is medical cannabis production, distribution, pharmacy supply, or export.
• ✓ Finished products require pharmaceutical-level approvals and quality controls.
• ✓ Legal advice is not optional; it is part of the operating model.

The main legal architecture combines medical cannabis legislation, narcotics law, pharmaceutical regulation, and industrial licensing. The Enterprise Greece licensing procedure describes the installation and operation approval path for pharmaceutical cannabis facilities. It points to a structured application process involving the competent ministries and the General Secretariat for Industry.

The medical cannabis business route normally begins with a Greek legal entity and a compliant site. The site must support secure cultivation, processing, and manufacturing within a controlled facility. The applicant then moves through installation approval, operational authorisation, and, crucially, product-level approvals. The National Organization for Medicines, known as EOF, sits at the centre of finished medicine evaluation. The official EOF website is the right starting point for current medicine-authorisation notices and regulatory updates.

International compliance sources such as GMP Compliance also describe Greece as a medical cannabis market where production, export, and pharmacy access are heavily linked to pharmaceutical quality expectations. In other words, the licence is not just permission to grow plants. It is permission to participate in a controlled medicinal supply chain.

A serious cannabis licence Greece plan should be built backwards from the final product and channel. Are you producing finished medical cannabis for Greek pharmacies? Are you building an export-focused facility? Are you developing extracts, oils, capsules, or another authorised final formulation? Each route changes the dossier, the business plan, the quality system, and the commercial partners required.

The broad sequence is usually: define the legal route, incorporate the Greek company, secure compliant land or premises, prepare the installation dossier, satisfy security and zoning requirements, build or validate the facility, obtain operational approval, and pursue EOF authorisation for finished products. Market reports from Prohibition Partners underline how Greece has been positioning itself as a medical production and export market, not a recreational retail destination.

This is where many investor decks become too optimistic. A beautiful brand, a retail concept, and imported product photos do not answer the licensing question. Greek authorities will care about land use, security, ownership, criminal-record restrictions, environmental and industrial approvals, product specifications, traceability, GMP readiness, pharmacovigilance, and whether the proposed activity fits the law. If you want a simpler wellness route, low-THC CBD products may be more realistic, but even that area has its own restrictions and recent changes around dried flower products.

💡 Pro Tip

Before paying for branding, packaging, or retail fit-out, pay for a licence feasibility review. If the activity cannot be authorised, everything downstream is just expensive decoration.

Greek patient access is pharmacy-based. Reporting from Business of Cannabis described the first medical cannabis prescriptions as a milestone for Greek healthcare after years of delay. That development did not create dispensaries. It brought authorised medical products into a prescription pathway involving doctors and pharmacies.

This means a company with a production licence still needs a legitimate route to patients or buyers. Domestic medical products must fit EOF rules and pharmacy distribution. Export products must fit Greek export rules and the destination country’s import rules. Consumer education also needs to stay careful. Readers comparing legal access with general wellness content should review our CBD oil daytime stress safety guide and CBD for sleep evidence guide, because responsible use language is part of trust.

Patient-facing summaries from The Cannigma and Leafwell reach the same broad conclusion: medical cannabis can be legal under defined conditions, while recreational cannabis remains illegal. For business owners, that means marketing must avoid implying adult-use availability, casual THC retail, or unsupported medical outcomes.

Low-THC hemp and CBD are often discussed in the same breath as medical cannabis, but they are not the same licensing category. Industrial hemp rules sit closer to agriculture and EU common agricultural policy. The European Parliament has documented the move from a 0.2% to a 0.3% THC field threshold for eligible hemp varieties in the EU framework through its Common Agricultural Policy reform coverage. Finished consumer products, however, can face separate national rules and safety controls.

Greek hemp guidance from specialist law firms such as Hlaw separates industrial hemp from medical cannabis with THC above the threshold. That separation is essential for planning. A CBD oil, a hemp textile business, a medical extract, and a THC flower product are not interchangeable from a regulatory perspective.

The extra complication in 2026 is product form. Dried cannabis or hemp flower has attracted stricter retail treatment, which means “low THC” does not automatically mean “safe to sell in any form.” If your business model depends on flower, pre-rolls, extracts, vapes, oils, cosmetics, or supplements, check the specific product category before assuming the general hemp conversation applies.

📝 Important Note

Do not treat THC percentage as the only compliance test. Product form, intended use, claims, channel, import status, prescription requirements, and EOF guidance can all change the answer.

A credible application begins with documents, not vibes. You need a defined applicant entity, ownership details, tax and social-security standing, land or premises rights, zoning support, technical drawings, facility descriptions, security measures, environmental analysis where required, supply-chain controls, and quality-management plans. The European Commission cosmetics guidance is also relevant if you plan CBD cosmetics rather than medicinal products, because claims and product category can move you into different compliance lanes.

For medical products, GMP is the cultural baseline. Even where a specific approval stage does not yet ask for every final document, investors should behave as if auditors will eventually inspect records, batch controls, standard operating procedures, staff training, deviations, recalls, and traceability. The European Medicines Agency GMP overview gives a useful sense of the pharmaceutical discipline expected in medicine manufacturing.

The commercial file matters too. Authorities and partners will want to understand whether the business is supplying Greek pharmacies, exporting to a defined market, manufacturing under contract, or developing proprietary branded medicines. If your plan includes wellness positioning, keep it evidence-based. Overpromising therapeutic benefits is a fast way to lose credibility with regulators, doctors, and serious customers.

The first mistake is asking for the wrong licence. If the business plan says “dispensary,” “club,” or “adult-use shop,” the Greek framework will not support it. The second mistake is separating cultivation from processing in a way that clashes with the unified facility logic described in official licensing materials. The third is underestimating security, because controlled-substance businesses are judged partly on whether diversion risks are controlled.

The fourth mistake is treating EOF approval as paperwork that comes after the “real business” is built. In medical cannabis, product approval is the business. Formulation, stability, analytics, packaging, labelling, adverse-event monitoring, and pharmacy distribution are not back-office details. They are what separates a legal medicinal product from an illegal cannabis product.

The fifth mistake is ignoring penalties. Our hemp flower ban consumer guide explains how quickly product-form rules can affect retail shelves. Businesses should also monitor official Greek Government Gazette publications and consult local counsel before importing, advertising, or selling anything with cannabinoids.

⚠️ Disclaimer

This article is for informational purposes only and does not constitute legal, medical, or investment advice. Cannabis rules in Greece are current as of June 2026 but may change. Always consult qualified Greek legal counsel, pharmaceutical regulatory advisers, and healthcare professionals before making business or treatment decisions. For our full disclaimer, visit cannastoreams.gr/disclaimer.